Eledon Pharmaceuticals (2TK) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2TK Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Eledon

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2TK Stock 12 Month Forecast

Average Price Target

€7.58

▲(125.55% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is €7.58 with a high forecast of €8.74 and a low forecast of €7.00. The average price target represents a 125.55% change from the last price of €3.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.7443927,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.578473673333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.99551416,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.7741840538461537,4.188368107692308,4.602552161538462,5.016736215384616,5.43092026923077,5.8451043230769235,6.259288376923077,6.673472430769231,7.087656484615385,7.50184053846154,7.916024592307693,8.330208646153848,{"y":8.7443927,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.6844979748717948,4.008995949743589,4.333493924615384,4.657991899487179,4.982489874358974,5.306987849230769,5.631485824102564,5.9559837989743585,6.280481773846153,6.604979748717948,6.929477723589743,7.253975698461538,{"y":7.578473673333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.36,3.6396549353846153,3.9193098707692307,4.198964806153846,4.478619741538461,4.758274676923077,5.037929612307693,5.317584547692308,5.5972394830769225,5.876894418461538,6.156549353846154,6.436204289230769,6.715859224615384,{"y":6.99551416,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€8.74

Average Price Target€7.58

Lowest Price Target€7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

€5.25→€7

Buy

108.20%

Upside

Reiterated

06/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert LeBoyer

Noble Financial

€8.74

Buy

160.25%

Upside

Reiterated

06/23/26

Analysts' Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€7

Buy

108.20%

Upside

Reiterated

06/22/26

Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Ufp Technologies (NASDAQ: UFPT), Eledon Pharmaceuticals (NASDAQ: ELDN) and CareDx (NASDAQ: CDNA)

Yi Chen

H.C. Wainwright

€7.87

Buy

134.22%

Upside

Reiterated

11/10/25

H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)

Thomas Smith

Leerink Partners

€7

Buy

108.20%

Upside

Reiterated

08/15/25

Eledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top Analyst

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

€5.25→€7

Buy

108.20%

Upside

Reiterated

06/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Robert LeBoyer

Noble Financial

€8.74

Buy

160.25%

Upside

Reiterated

06/23/26

Analysts' Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€7

Buy

108.20%

Upside

Reiterated

06/22/26

Guggenheim Sticks to Its Buy Rating for Eledon Pharmaceuticals (ELDN)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Ufp Technologies (NASDAQ: UFPT), Eledon Pharmaceuticals (NASDAQ: ELDN) and CareDx (NASDAQ: CDNA)

Yi Chen

H.C. Wainwright

€7.87

Buy

134.22%

Upside

Reiterated

11/10/25

H.C. Wainwright Remains a Buy on Eledon Pharmaceuticals (ELDN)

Thomas Smith

Leerink Partners

€7

Buy

108.20%

Upside

Reiterated

08/15/25

Eledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top Analyst

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eledon Pharmaceuticals

3 Months

Robert LeBoyerNoble Financial

Success Rate

10/18 ratings generated profit

Average Return

+11.71%

Copying Robert LeBoyer's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +11.71% per trade.

1 Year

Robert LeBoyerNoble Financial

Success Rate

15/18 ratings generated profit

Average Return

+42.44%

Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +42.44% per trade.

2 Years

Robert LeBoyerNoble Financial

Success Rate

16/18 ratings generated profit

Average Return

+50.41%

Copying Robert LeBoyer's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +50.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2TK Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2TK has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2TK average Analyst price target in the past 3 months is 7.58.

Each month's total comprises the sum of three months' worth of ratings.

2TK Financial Forecast

2TK Earnings Forecast

Next quarter’s earnings estimate for 2TK is -€0.14 with a range of -€0.17 to -€0.08. The previous quarter’s EPS was -€0.29. 2TK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 39.63% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.

No data currently available

2TK Sales Forecast

Next quarter’s sales forecast for 2TK is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 2TK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 43.02% of the time in the same period. In the last calendar year 2TK has Performed in-line its overall industry.

2TK Stock Forecast FAQ

What is DE:2TK’s average 12-month price target, according to analysts?

Based on analyst ratings, Eledon Pharmaceuticals, Inc.’s 12-month average price target is 7.58.

What is DE:2TK’s upside potential, based on the analysts’ average price target?

Eledon Pharmaceuticals, Inc. has 125.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eledon Pharmaceuticals, Inc. a Buy, Sell or Hold?

Eledon Pharmaceuticals, Inc. has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Eledon Pharmaceuticals, Inc.’s share price target?

The average share price target for Eledon Pharmaceuticals, Inc. is 7.58. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €8.74 ,and the lowest forecast is €7.00. The average share price target represents 125.55% Increase from the current price of €3.36.

What do analysts say about Eledon Pharmaceuticals, Inc.?

Eledon Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Eledon Pharmaceuticals, Inc.?

To buy shares of DE:2TK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eledon Pharmaceuticals (2TK) Stock Forecast & Price Target

2TK Analyst Ratings

2TK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eledon Pharmaceuticals

2TK Analyst Recommendation Trends

2TK Financial Forecast

2TK Earnings Forecast

2TK Sales Forecast

2TK Stock Forecast FAQ

Detailed List of Analyst Forecasts